— Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61.
— Total revenue stood at $1.96 million vs. $3.68 million expected.
— Sage expects revenue growth of ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD), will be modest over the next couple of quarters with an increase in the rate of growth of ZULRESSO revenue anticipated in the second half of 2020.
— The company will be having a meeting with the FDA in the first quarter of 2020 to discuss about Zuranolone, the clinical program for the treatment of major depressive disorder (MDD) and PPD.
— R&D expenses were $91.3 million compared to $88.8 million in the prior-year quarter. SG&A expenses were $85.1 million vs. $75.7 million in the fourth quarter of 2018.
— SAGE stock, which ended down 1.24% at $63.65, had dropped 12% so far this year.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Will the pandemic help or hurt Target (TGT)?
As the coronavirus pandemic rages on, major retailers continue to experience huge demand for food and essential items both in their stores and online. Target Corporation (NYSE: TGT) is one
GameStop (GME) swings to profit in Q4, beats estimates
GameStop Corp. (NYSE: GME) swung to a profit in the fourth quarter of 2019 from a loss last year, helped by lower costs and expenses despite a 28% dip in
Is Skechers’ global footprint strong enough to tide over present crisis?
Footwear maker Skechers USA, Inc. (NYSE: SKX) lost considerable market value in recent weeks and under-performed the industry, amid growing fears that a recession is imminent. The crisis has left